# National Health Investors Inc: financial statements, quarterly

NHI · NYSE · CIK 877860 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nhi.md) · [Financials](/companies/nhi/financials.md) · [Filings](/companies/nhi/filings.md) · [Insiders](/companies/nhi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nhi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [12.4](/filings/0000877860-24-000080.md) | [12.9 d](/filings/0000877860-26-000053.md) | [13.3](/filings/0000877860-25-000095.md) | [13.4](/filings/0000877860-25-000135.md) | [13.8](/filings/0000877860-25-000183.md) | [14.0 d](/filings/0000877860-26-000053.md) | [13.9](/filings/0000877860-26-000135.md) | [14.2](/filings/0000877860-26-000199.md) | [21.2](/filings/0000877860-25-000183.md) | [30.7 d](/filings/0000877860-26-000053.md) | [37.1](/filings/0000877860-26-000135.md) | [44.8](/filings/0000877860-26-000199.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [15.1](/filings/0000877860-24-000080.md) | [14.9 d](/filings/0000877860-26-000053.md) | [14.9](/filings/0000877860-25-000095.md) | [14.9](/filings/0000877860-25-000135.md) | [14.9](/filings/0000877860-25-000183.md) | [15.2 d](/filings/0000877860-26-000053.md) | [14.3](/filings/0000877860-26-000135.md) | [15.0](/filings/0000877860-26-000199.md) | [13.8](/filings/0000877860-25-000183.md) | [14.3 d](/filings/0000877860-26-000053.md) | [15.0](/filings/0000877860-26-000135.md) | [15.8](/filings/0000877860-26-000199.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0000877860-26-000199.md) | not reported | not reported | not reported | [0.7](/filings/0000877860-26-000199.md) |
| Net income | $m | [29.3](/filings/0000877860-24-000080.md) | [32.0 d](/filings/0000877860-26-000053.md) | [30.9](/filings/0000877860-25-000095.md) | [35.3](/filings/0000877860-25-000135.md) | [28.5](/filings/0000877860-25-000183.md) | [43.2 d](/filings/0000877860-26-000053.md) | [34.2](/filings/0000877860-26-000135.md) | [37.0](/filings/0000877860-26-000199.md) | [32.9](/filings/0000877860-25-000183.md) | [38.2 d](/filings/0000877860-26-000053.md) | [40.1](/filings/0000877860-26-000135.md) | [55.7](/filings/0000877860-26-000199.md) |
| Diluted EPS | $ per share | [0.68](/filings/0000877860-24-000080.md) | not reported | [0.71](/filings/0000877860-25-000095.md) | [0.81](/filings/0000877860-25-000135.md) | [0.65](/filings/0000877860-25-000183.md) | not reported | [0.74](/filings/0000877860-26-000135.md) | [0.79](/filings/0000877860-26-000199.md) | [0.69](/filings/0000877860-25-000183.md) | not reported | [0.82](/filings/0000877860-26-000135.md) | [1.15](/filings/0000877860-26-000199.md) |
| Basic EPS | $ per share | [0.68](/filings/0000877860-24-000080.md) | not reported | [0.71](/filings/0000877860-25-000095.md) | [0.81](/filings/0000877860-25-000135.md) | [0.66](/filings/0000877860-25-000183.md) | not reported | [0.75](/filings/0000877860-26-000135.md) | [0.79](/filings/0000877860-26-000199.md) | [0.69](/filings/0000877860-25-000183.md) | not reported | [0.83](/filings/0000877860-26-000135.md) | [1.15](/filings/0000877860-26-000199.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [16.6](/filings/0000877860-24-000080.md) | [22.3](/filings/0000877860-26-000053.md) | [11.4](/filings/0000877860-25-000095.md) | [14.8](/filings/0000877860-25-000135.md) | [15.6](/filings/0000877860-25-000183.md) | [24.3](/filings/0000877860-26-000199.md) | [135](/filings/0000877860-26-000135.md) | [18.6](/filings/0000877860-26-000199.md) | [81.6](/filings/0000877860-25-000183.md) | [19.6](/filings/0000877860-26-000199.md) | [24.9](/filings/0000877860-26-000135.md) | [30.4](/filings/0000877860-26-000199.md) |
| Total assets | $m | [2,499](/filings/0000877860-24-000080.md) | [2,488](/filings/0000877860-25-000027.md) | [2,478](/filings/0000877860-25-000095.md) | [2,477](/filings/0000877860-25-000135.md) | [2,460](/filings/0000877860-24-000080.md) | [2,614](/filings/0000877860-26-000053.md) | [2,783](/filings/0000877860-25-000095.md) | [2,696](/filings/0000877860-25-000135.md) | [2,690](/filings/0000877860-25-000183.md) | [2,797](/filings/0000877860-26-000199.md) | [2,890](/filings/0000877860-26-000135.md) | [2,964](/filings/0000877860-26-000199.md) |
| Total liabilities | $m | [1,218](/filings/0000877860-23-000108.md) | [1,214](/filings/0000877860-25-000027.md) | [1,211](/filings/0000877860-24-000047.md) | [1,213](/filings/0000877860-24-000065.md) | [1,213](/filings/0000877860-24-000080.md) | [1,229](/filings/0000877860-26-000053.md) | [1,338](/filings/0000877860-25-000095.md) | [1,199](/filings/0000877860-25-000135.md) | [1,192](/filings/0000877860-25-000183.md) | [1,257](/filings/0000877860-26-000199.md) | [1,357](/filings/0000877860-26-000135.md) | [1,375](/filings/0000877860-26-000199.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,260](/filings/0000877860-23-000108.md) | [1,254](/filings/0000877860-25-000027.md) | [1,248](/filings/0000877860-24-000047.md) | [1,244](/filings/0000877860-24-000065.md) | [1,229](/filings/0000877860-24-000080.md) | [1,366](/filings/0000877860-26-000053.md) | [1,426](/filings/0000877860-25-000095.md) | [1,480](/filings/0000877860-25-000135.md) | [1,481](/filings/0000877860-25-000183.md) | [1,522](/filings/0000877860-26-000199.md) | [1,515](/filings/0000877860-26-000135.md) | [1,571](/filings/0000877860-26-000199.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [49.7 d](/filings/0000877860-24-000080.md) | [53.2 d](/filings/0000877860-26-000053.md) | [40.8](/filings/0000877860-25-000095.md) | [60.7 d](/filings/0000877860-25-000135.md) | [48.6 d](/filings/0000877860-25-000183.md) | [57.6 d](/filings/0000877860-26-000053.md) | [46.5](/filings/0000877860-26-000135.md) | [59.8 d](/filings/0000877860-26-000199.md) | [62.5 d](/filings/0000877860-25-000183.md) | [67.7 d](/filings/0000877860-26-000053.md) | [53.4](/filings/0000877860-26-000135.md) | [65.0 d](/filings/0000877860-26-000199.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | [111 d](/filings/0000877860-26-000053.md) | [85.2](/filings/0000877860-26-000135.md) | not reported | not reported | [143 d](/filings/0000877860-26-000053.md) | [109](/filings/0000877860-26-000135.md) | not reported |
| Dividends paid | $m | [39.1 d](/filings/0000877860-24-000080.md) | [39.1 d](/filings/0000877860-26-000053.md) | [39.1](/filings/0000877860-25-000095.md) | [39.1 d](/filings/0000877860-25-000135.md) | [39.1 d](/filings/0000877860-25-000183.md) | [39.3 d](/filings/0000877860-26-000053.md) | [41.1](/filings/0000877860-26-000135.md) | [42.0 d](/filings/0000877860-26-000199.md) | [42.7 d](/filings/0000877860-25-000183.md) | [43.8 d](/filings/0000877860-26-000053.md) | [44.4](/filings/0000877860-26-000135.md) | [44.6 d](/filings/0000877860-26-000199.md) |
| Share repurchases | $m | [0.0 d](/filings/0000877860-23-000108.md) | [0.0 d](/filings/0000877860-25-000027.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [44.4](/filings/0000877860-23-000108.md) | [43.4](/filings/0000877860-24-000047.md) | [43.4](/filings/0000877860-24-000065.md) | [43.4](/filings/0000877860-24-000080.md) | [43.4](/filings/0000877860-25-000095.md) | [43.6](/filings/0000877860-25-000135.md) | [44.0](/filings/0000877860-25-000183.md) | [45.9](/filings/0000877860-26-000135.md) | [46.8](/filings/0000877860-26-000199.md) | [47.6](/filings/0000877860-25-000183.md) | [48.5](/filings/0000877860-26-000135.md) | [48.5](/filings/0000877860-26-000199.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,110,434 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0000877860-26-000199.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.